TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33879481

Group type: EXPERIMENTAL
Intervention: Stage I - Observational study on the prevalence of urinary incontinence and its associated factors; prevalence ratio used as an association measure.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stage II - Longitudinal study over 2 years; evaluates functional and continence decline, falls, hospitalisations, mortality, and impact of COVID-19.
Number of subjects: 0
Study: 33879499

Group type: EXPERIMENTAL
Intervention: Chronic OME patients
Number of subjects: 123

Group type: COMPARATOR
Intervention: Controls (healthy subjects)
Number of subjects: 123
Study: 33879515

Group type: EXPERIMENTAL
Intervention: Insulin-induced blood glucose normalization (from 7.6±0.4 mmol/L to 4.5±0.07 mmol/L for 1 hour)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Insulin-induced blood glucose normalization
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group maintained at 4.9±0.1 mmol/L
Number of subjects: 23
Study: 33879601

Group type: EXPERIMENTAL
Intervention: pembrolizumab 2 mg/kg every 3 weeks for ≤2 years
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: salvage therapies including chemotherapies and immunotherapies
Number of subjects: 50
Study: 33879722

Group type: EXPERIMENTAL
Intervention: Aggressive hydration with Lactated Ringer Solution
Number of subjects: 2200
Study: 33879819

Group type: EXPERIMENTAL
Intervention: Increased coupling between right temporoparietal and anterior cingulate cortex for repeated objects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetition suppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial support for predictions of the Facilitation and Sharpening models in the left fusiform gyrus and left frontal cortex
Number of subjects: 0
Study: 33880400

Group type: EXPERIMENTAL
Intervention: Functional endoscopy
Number of subjects: 0
Study: 33870087

Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 0
Study: 33880438

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seropositivity
Number of subjects: 1364

Group type: COMPARATOR
Intervention: Intensive Therapy Unit (ITU) workers
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 1364

Group type: COMPARATOR
Intervention: White HCWs
Number of subjects: 1364
Study: 33880504

Group type: EXPERIMENTAL
Intervention: Calibrated carbohydrate density
Number of subjects: 81954

Group type: EXPERIMENTAL
Intervention: Calibrated protein density
Number of subjects: 81954
Study: 33880555

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (1 mg/kg and 3 mg/kg respectively, intravenously every 3 weeks ×4, followed by nivolumab 3 mg/kg every 2 weeks until progression, unacceptable toxicity, or 24 months)
Number of subjects: 119
Study: 33880939

Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet analgesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33881209

Group type: EXPERIMENTAL
Intervention: Prexasertib (LY2606368) administered intravenously on days 1 and 15 of a 28-day cycle at dose levels of 80, 100, 125, and 150 mg/m²
Number of subjects: 30
Study: 33881400

Group type: EXPERIMENTAL
Intervention: V-LAP technology (intracardiac microsensors)
Number of subjects: 14
Study: 33881463

Group type: EXPERIMENTAL
Intervention: Caplacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33881718

Group type: EXPERIMENTAL
Intervention: Qishe Pill (3-4 g/kg for 4 weeks)
Number of subjects: 2023
Study: 33881949

Group type: EXPERIMENTAL
Intervention: Collaboration with community stakeholders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 33882028

Group type: EXPERIMENTAL
Intervention: ATP 360 nutraceutical energy formula for 8 weeks
Number of subjects: 11
Study: 33882070

Group type: EXPERIMENTAL
Intervention: eNose-TB screening tool
Number of subjects: 1778

Group type: COMPARATOR
Intervention: Clinical symptoms and chest radiology (standard screening)
Number of subjects: 1778

Group type: EXPERIMENTAL
Intervention: eNose-TB screening algorithm
Number of subjects: 1778
Study: 33882092

Group type: EXPERIMENTAL
Intervention: Intervention (BCPP interventions to improve linkage to care, retention, viral load coverage, and service delivery)
Number of subjects: 3657

Group type: EXPERIMENTAL
Intervention: Intervention (Tracking and tracing efforts)
Number of subjects: 3657

Group type: EXPERIMENTAL
Intervention: Intervention (Retention in care)
Number of subjects: 3657

Group type: EXPERIMENTAL
Intervention: Intervention (Viral load results)
Number of subjects: 3657
Study: 33882143

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus nivolumab
Number of subjects: 19
Study: 33882147

Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA) use
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA) use (adjusted for prior MPA discontinuation)
Number of subjects: 700
Study: 33882374

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection in cancer patients
Number of subjects: 39

Group type: COMPARATOR
Intervention: SARS-CoV-2 infection in non-cancer patients
Number of subjects: 39
Study: 33882698

Group type: EXPERIMENTAL
Intervention: Heat challenge (HC) with 35°C exposure after acclimation to 27°C baseline (BL)
Number of subjects: 20
Study: 33882792

Group type: EXPERIMENTAL
Intervention: MRgHIFU (Profound Sonalleve)
Number of subjects: 11
Study: 33882846

Group type: EXPERIMENTAL
Intervention: Rilonacept (IL-1α/IL-1β cytokine trap) administered weekly during a 6-week base treatment period plus an optional 18-week extension period.
Number of subjects: 25
Study: 33882862

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) performed by a nurse and physician, adapted to primary care context, during a two-year follow-up period.
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 1308
Study: 33883015

Group type: EXPERIMENTAL
Intervention: Multisite transcranial direct current stimulation combined with cognitive training (24 sessions, 30 minutes each, 3 times a week, with stimulation of different brain areas every 10 minutes).
Number of subjects: 2
Study: 33883033

Group type: EXPERIMENTAL
Intervention: ThinkCancer! intervention (educational behaviour change workshop for GPs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study: 33883035

Group type: EXPERIMENTAL
Intervention: SDM decision tool (CV PREVENTION CHOICE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SDM
Number of subjects: 0
Study: 33883176

Group type: EXPERIMENTAL
Intervention: Lutetium-177-PSMA-617
Number of subjects: 10
Study: 33883177

Group type: EXPERIMENTAL
Intervention: Sabatolimab plus spartalizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sabatolimab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spartalizumab
Number of subjects: 0
Study: 33883194

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS) for coronary artery disease (CAD)
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Genetic factors
Number of subjects: 1371
Study: 33883258

Group type: EXPERIMENTAL
Intervention: rhIL-15 CIV-5, 3 µg (n=4)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: rhIL-15 CIV-5, 4 µg (n=3)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: rhIL-15 CIV-5, 5 µg/kg/day (n=4)
Number of subjects: 11
Study: 33883548

Group type: EXPERIMENTAL
Intervention: Cell-free RNA (cfRNA) analysis in cancer patients
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Detection of dark channel biomarker (DCB) genes in cancer patients
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: cfRNA as a cancer detection method
Number of subjects: 165
Study: 33884298

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard-of-care (control group)
Number of subjects: 250
Study: 33884617

Group type: EXPERIMENTAL
Intervention: Individual cognitive behavioural therapy (CBT)-based psychotherapy
Number of subjects: 21414

Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy (DBT)
Number of subjects: 21414

Group type: EXPERIMENTAL
Intervention: Mentalisation-based therapy (MBT)
Number of subjects: 21414

Group type: EXPERIMENTAL
Intervention: Group-based emotion-regulation psychotherapy
Number of subjects: 21414

Group type: EXPERIMENTAL
Intervention: Various forms of DBT (group-based skills training, individual skills training, experimental DBT)
Number of subjects: 21414

Group type: EXPERIMENTAL
Intervention: Provision of information and support (START and SUPRE-MISS models)
Number of subjects: 21414

Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy, case management, GP management, remote contact interventions, other multimodal interventions, brief emergency department-based interventions
Number of subjects: 21414
Study: 33884961

Group type: EXPERIMENTAL
Intervention: PARPi treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: In vitro tumor treatment with a PARPi
Number of subjects: 13
Study: 33885047

Group type: EXPERIMENTAL
Intervention: General and epidural anesthesia during elective knee replacement surgery
Number of subjects: 18
Study: 33885048

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 72
Study: 33885369

Group type: EXPERIMENTAL
Intervention: Digital health intervention (DHI) using animated health videos and InfoSpots; exposure to 3 different health animations once on a tablet device.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Digital health intervention (DHI)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 600
Study: 33885368

Group type: EXPERIMENTAL
Intervention: Smart Walk intervention delivered through smartphone app and text messages
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Smart Walk intervention
Number of subjects: 20
Study: 33886075

Group type: EXPERIMENTAL
Intervention: Time-of-Flight surface imaging technique for tidal volume measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time-of-Flight surface imaging technique for respiratory rate measurement
Number of subjects: 0
Study: 33886085

Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 33886789

Group type: EXPERIMENTAL
Intervention: Bronchiectasis group
Number of subjects: 74
Study: 33887060

Group type: EXPERIMENTAL
Intervention: Cough augmentation techniques (manual assisted cough, mechanical insufflation, manual and mechanical breathstacking, mechanical insufflation-exsufflation, glossopharyngeal breathing, combination techniques)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Alternative cough augmentation techniques
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Cough augmentation techniques
Number of subjects: 287
Study: 33887074

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 9556

Group type: EXPERIMENTAL
Intervention: Tobacco Use
Number of subjects: 9556

Group type: EXPERIMENTAL
Intervention: Alcohol Consumption
Number of subjects: 9556

Group type: EXPERIMENTAL
Intervention: Weight Gain
Number of subjects: 9556

Group type: EXPERIMENTAL
Intervention: Improved Behaviors
Number of subjects: 9556

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 9556
Study: 33887119

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasonography
Number of subjects: 41
Study: 33888067

Group type: EXPERIMENTAL
Intervention: Aripiprazole (1-15 mg/day)
Number of subjects: 510
Study: 33888232

Group type: EXPERIMENTAL
Intervention: Balloon-Expandable Transcatheter Heart Valves
Number of subjects: 0
Study: 33888241

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33888530

Group type: EXPERIMENTAL
Intervention: Patient-reported assessment of shoulder function (Oxford Shoulder Score (OSS)) at 6 months post-surgery
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Shoulder stiffness occurrence at 6 months post-surgery
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Shoulder range of motion and strength (Constant Score) at 6 and 12 months post-surgery
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Tendon repair integrity status assessed by ultrasound at 12 months post-surgery
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Patient-reported questionnaires at 6, 12, and 24 months for functional scores, anxiety and depression scores, working status, sports activities, and quality of life (European Quality of Life 5 Dimensions 5 Level questionnaire)
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) documented according to a consensus core event set (CES)
Number of subjects: 970
Study: 33888591

Group type: EXPERIMENTAL
Intervention: Postoperative cognitive dysfunction
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Physical Component Score (PCS)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Mental Component Score (MCS)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Postoperative cognitive changes
Number of subjects: 142
Study: 33888899

Group type: EXPERIMENTAL
Intervention: 4-1BB-costimulated CD22 CAR T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD19-directed CAR T cells
Number of subjects: 0
Study: 33888901

Group type: EXPERIMENTAL
Intervention: Belzutifan (MK-6482) administered orally at 120 mg once daily in patients with ccRCC (n=55)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Belzutifan (MK-6482) administered orally at various doses in dose-escalation cohort (n=43)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Belzutifan (MK-6482) administered orally at various doses
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Belzutifan (MK-6482)
Number of subjects: 98
Study: 33888974

Group type: EXPERIMENTAL
Intervention: Posterior chamber intraocular lenses implantation during cataract surgery
Number of subjects: 34
Study: 33889025

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 1965

Group type: COMPARATOR
Intervention: Clinician diagnosis
Number of subjects: 1965
Study: 33889959

Group type: EXPERIMENTAL
Intervention: FSHR SNPs (rs6165, rs6166, rs1394205)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: FSHR SNPs (rs1394205)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: FSHR variant rs6166
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: FSHR variant rs6165
Number of subjects: 368
Study: 33890058

Group type: EXPERIMENTAL
Intervention: Metreleptin (14 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Metreleptin withdrawal (14 days)
Number of subjects: 25
Study: 33890580

Group type: EXPERIMENTAL
Intervention: GIMEMA-ALLIANCE digital health platform
Number of subjects: 116
Study: 33890856

Group type: EXPERIMENTAL
Intervention: HeartBeat algorithm using MediBeat app and Contec CMS50EW pulse oximeter
Number of subjects: 62

Group type: COMPARATOR
Intervention: Manual blood pressure measurement
Number of subjects: 62
Study: 33890857

Group type: EXPERIMENTAL
Intervention: Fit2ThriveMB intervention (smartphone-delivered, home-based PA intervention)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Attention-control education condition
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fit2ThriveMB intervention
Number of subjects: 50
Study: 33891139

Group type: EXPERIMENTAL
Intervention: Indocyanine green retention rate at 15 min (ICG-R15)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hepatic Venous Portal Gradient (HVPG)
Number of subjects: 50
Study: 33891250

Group type: EXPERIMENTAL
Intervention: Postoperative perfusion index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in preoperative baseline perfusion index (ΔPI-pre)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in postoperative perfusion index (ΔPI-po)
Number of subjects: 0
Study: 33891293

Group type: EXPERIMENTAL
Intervention: Anidulafungin 200 mg IV once, followed by 100 mg IV once daily for ≥ 5 to ≥ 10 days, with a switch to oral voriconazole/fluconazole permitted in all but one study.
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Anidulafungin treatment
Number of subjects: 139
Study: 33891312

Group type: EXPERIMENTAL
Intervention: Accidental dural puncture
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control (uneventful epidural insertion)
Number of subjects: 270
Study: 33891621

Group type: EXPERIMENTAL
Intervention: Standard of care EoE treatment for 2 months
Number of subjects: 25
Study: 33892094

Group type: EXPERIMENTAL
Intervention: Instructor-led group yoga sessions (8 sessions)
Number of subjects: 15
Study: 33892111

Group type: EXPERIMENTAL
Intervention: Extended-release methylphenidate (MPH-MLR)
Number of subjects: 90
Study: 33892122

Group type: EXPERIMENTAL
Intervention: Valiant Evo thoracic stent graft system
Number of subjects: 83
Study: 33892407

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks) + Metronomic cyclophosphamide (25 mg/m2)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nivolumab + Metronomic cyclophosphamide
Number of subjects: 13
Study: 33892489

Group type: EXPERIMENTAL
Intervention: GARFIELD-AF risk tool
Number of subjects: 52080
Study: 33892660

Group type: EXPERIMENTAL
Intervention: NutriSTEP® single question on food insecurity
Number of subjects: 1174

Group type: COMPARATOR
Intervention: Hunger Vital Sign™
Number of subjects: 1174
Study: 33892693

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Contraceptives
Number of subjects: 214
Study: 33892740

Group type: EXPERIMENTAL
Intervention: Ladnaan, a culturally tailored parenting program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 33893160

Group type: EXPERIMENTAL
Intervention: APL9 score based on genomic and transcriptomic analysis
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Molecular markers identified in the study
Number of subjects: 348
Study: 33893174

Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided thoracic epidural catheter placement
Number of subjects: 38
Study: 33893210

Group type: EXPERIMENTAL
Intervention: HIV positive subjects receiving antiviral treatment (32%)
Number of subjects: 510

Group type: COMPARATOR
Intervention: HIV negative subjects receiving antiviral treatment (6%)
Number of subjects: 510
Study: 33893289

Group type: EXPERIMENTAL
Intervention: Circulating tumour DNA sequencing
Number of subjects: 800

Group type: COMPARATOR
Intervention: Fulvestrant treatment
Number of subjects: 800
Study: 33893692

Group type: EXPERIMENTAL
Intervention: Durvalumab (1,500 mg every 4 weeks × 13) and Tremelimumab (75 mg Q4 weeks × 7, then Q12 weeks × 2)
Number of subjects: 50
Study: 33893973

Group type: EXPERIMENTAL
Intervention: Oral administration of N-acetylmannosamine (ManNAc)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: N-acetylmannosamine (ManNAc)
Number of subjects: 34
Study: 33894353

Group type: EXPERIMENTAL
Intervention: Laboratory-confirmed symptomatic dengue infection
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: Inapparent primary dengue infection
Number of subjects: 3300
Study: 33894474

Group type: EXPERIMENTAL
Intervention: High NETs group (60 patients)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Low NETs group (44 patients)
Number of subjects: 104
Study: 33894633

Group type: EXPERIMENTAL
Intervention: Circulating Tumor Cell (CTC) count determined on the Epic Sciences platform
Number of subjects: 278

Group type: COMPARATOR
Intervention: CTC enumeration using CellSearch® Circulating Tumor Cell Kit
Number of subjects: 278
Study: 33894747

Group type: EXPERIMENTAL
Intervention: Targeted lateral position with personalized PEEP
Number of subjects: 5

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 5
Study: 33894753

Group type: EXPERIMENTAL
Intervention: Chinese version of ASESp (ASESp-CH)
Number of subjects: 86
Study: 33895322

Group type: EXPERIMENTAL
Intervention: GRAd-COV2 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-fusion stabilized Spike antigen
Number of subjects: 0
Study: 33895695

Group type: COMPARATOR
Intervention: Year of metastatic diagnosis 2016
Number of subjects: 20446

Group type: COMPARATOR
Intervention: Year of metastatic diagnosis 2016 in HER2+ subcohort
Number of subjects: 20446

Group type: COMPARATOR
Intervention: Year of metastatic diagnosis 2016 in TNBC
Number of subjects: 20446

Group type: COMPARATOR
Intervention: Year of metastatic diagnosis 2016 in HR+/HER2-
Number of subjects: 20446

Group type: EXPERIMENTAL
Intervention: Exposure to newly released anti-HER2 therapies (e.g. pertuzumab) from 2016 onwards
Number of subjects: 20446

Group type: EXPERIMENTAL
Intervention: Use of everolimus or eribulin in HR+/HER2- and TNBC cohorts
Number of subjects: 20446
Study: 33895711

Group type: EXPERIMENTAL
Intervention: Assisted partner services (APS) using community-embedded peer educators (PEs) to identify and link partners to care.
Number of subjects: 1000
Study: 33895716

Group type: EXPERIMENTAL
Intervention: Existential distress assessment through self-report questionnaires and structured diagnostic interviews at baseline and 6-month follow-up.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Longitudinal assessment of existential distress at five points (baseline, 3, 6, 9, and 12 months).
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Multiple linear and logistic regression analyses to calculate the predictive impact of existential distress on end-of-life outcomes.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Growth mixture models to analyze longitudinal trajectories of existential distress.
Number of subjects: 1000
Study: 33895806

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study: 33895809

Group type: EXPERIMENTAL
Intervention: Genomic classification (including transcriptome sequencing, gene expression profiling, cytogenetics, and fusion polymerase chain reaction)
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: High-risk genotypes (Ph-like, KMT2A-AFF1, low-hypodiploid/near-haploid, BCL2/MYC-rearranged)
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Intermediate-risk genotypes (PAX5alt, ZNF384/-like, MEF2D-rearranged)
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Standard risk (DUX4-rearranged, ETV6-RUNX1/-like, TCF3-PBX1, PAX5 P80R, high-hyperdiploid)
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: IKZF1 alterations and TP53 mutations
Number of subjects: 1229
Study: 33895822

Group type: EXPERIMENTAL
Intervention: Normal sleep condition
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sleep deprivation condition
Number of subjects: 16
Study: 33895874

Group type: EXPERIMENTAL
Intervention: Oral paromomycin and metronidazole
Number of subjects: 92